InvestSMART

Heartland Group Holdings Limited (ASX:HGH)

ALERT: Price-sensitive ASX Announcement for HGH
Current share price for HGH : $1.000 -0.02 (-1.96%)+
Announcement
Release
20 Aug 2026 7:42AM
Price at Release
$1.020
Full Release
download
Summary
Heartland Group Holdings Limited reported a strong financial performance in FY2026, meeting all underlying guidance metrics. The company achieved an NPAT of $93.2 million, with underlying NPAT rising from $46.9 million to $90.4 million. ROE improved to 7.3%, and average NIM expanded by 36 bps to 3.98%. Operational efficiency also improved, with the CTI ratio decreasing to 54.6%. Heartland's asset quality strengthened significantly, with a reduction in impairment expense ratio to 0.45%. Reverse Mortgages performed well in both New Zealand and Australia, with receivables increasing by 16.8% and 19.7% respectively. The company concluded its NSA realisation programme successfully and announced a proposed merger with TSB to create a challenger bank in New Zealand. Looking ahead to FY2027, Heartland anticipates further growth in various sectors, including Reverse Mortgages and Livestock Finance.
Key Points
  • Heartland achieved NPAT of $93.2m, underlying NPAT of $90.4m.
  • ROE improved to 7.3%; underlying ROE up to 7.1%.
  • Average NIM expanded to 3.98%.
  • CTI ratio improved to 54.6%.
  • Impairment expense ratio decreased to 0.45%.
  • Reverse Mortgages receivables up 16.8% and 19.7% in NZ and AU.
  • Successfully completed NSA realisation programme.
  • Proposed merger with TSB for a new challenger bank.
  • FY2027 outlook includes growth in Reverse Mortgages and Livestock Finance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.